AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 163 filers reported holding AGIOS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 1.81 and the average weighting 0.1%.
Links
Filings
- All filings
- Annual reports (20-F)
- Quarterly reports (6-K)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,993 | -33.4% | 121,008 | -23.8% | 0.00% | -33.3% |
| Q2 2023 | $4,495 | +104.2% | 158,725 | +65.6% | 0.00% | +200.0% |
| Q1 2023 | $2,201 | -38.9% | 95,829 | -25.3% | 0.00% | -50.0% |
| Q4 2022 | $3,600 | -99.9% | 128,210 | +34.3% | 0.00% | -33.3% |
| Q3 2022 | $2,701,000 | +526.7% | 95,500 | +391.8% | 0.00% | – |
| Q2 2022 | $431,000 | -77.5% | 19,420 | -70.5% | 0.00% | -100.0% |
| Q1 2022 | $1,918,000 | -58.2% | 65,880 | -52.8% | 0.00% | +100.0% |
| Q4 2021 | $4,590,000 | +276.2% | 139,630 | +428.4% | 0.00% | 0.0% |
| Q3 2021 | $1,220,000 | -58.5% | 26,424 | -50.5% | 0.00% | 0.0% |
| Q2 2021 | $2,940,000 | -38.5% | 53,378 | -42.4% | 0.00% | -66.7% |
| Q1 2021 | $4,782,000 | -1.0% | 92,619 | -16.9% | 0.00% | 0.0% |
| Q4 2020 | $4,829,000 | +20.2% | 111,446 | -2.8% | 0.00% | +50.0% |
| Q3 2020 | $4,016,000 | -29.2% | 114,699 | +8.1% | 0.00% | -50.0% |
| Q2 2020 | $5,673,000 | +45.3% | 106,072 | -3.6% | 0.00% | +33.3% |
| Q1 2020 | $3,904,000 | +247.0% | 110,009 | +366.9% | 0.00% | +200.0% |
| Q4 2019 | $1,125,000 | +922.7% | 23,562 | +595.2% | 0.00% | – |
| Q3 2019 | $110,000 | -97.3% | 3,389 | -95.8% | 0.00% | -100.0% |
| Q2 2019 | $4,050,000 | +1482.0% | 81,221 | +2038.5% | 0.00% | – |
| Q1 2019 | $256,000 | -96.3% | 3,798 | -97.5% | 0.00% | -100.0% |
| Q4 2018 | $7,010,000 | +1920.2% | 152,019 | +3281.2% | 0.01% | – |
| Q3 2018 | $347,000 | -93.0% | 4,496 | -92.3% | 0.00% | -100.0% |
| Q2 2018 | $4,934,000 | -1.2% | 58,581 | -4.1% | 0.00% | 0.0% |
| Q1 2018 | $4,996,000 | +263.6% | 61,081 | +154.2% | 0.00% | +300.0% |
| Q4 2017 | $1,374,000 | -28.4% | 24,030 | -16.4% | 0.00% | -50.0% |
| Q3 2017 | $1,918,000 | -35.8% | 28,736 | -50.5% | 0.00% | -33.3% |
| Q2 2017 | $2,989,000 | -35.4% | 58,085 | -26.7% | 0.00% | -40.0% |
| Q1 2017 | $4,629,000 | +112.0% | 79,261 | +51.5% | 0.01% | +150.0% |
| Q4 2016 | $2,183,000 | -92.0% | 52,318 | -89.9% | 0.00% | -93.3% |
| Q3 2016 | $27,426,000 | +342725.0% | 519,238 | +274629.1% | 0.03% | – |
| Q2 2016 | $8,000 | -94.9% | 189 | -95.1% | 0.00% | – |
| Q1 2016 | $156,000 | +22.8% | 3,893 | +95.9% | 0.00% | – |
| Q4 2015 | $127,000 | -85.3% | 1,987 | -83.9% | 0.00% | -100.0% |
| Q3 2015 | $865,000 | -6.9% | 12,366 | +47.8% | 0.00% | 0.0% |
| Q2 2015 | $929,000 | +1307.6% | 8,365 | +1105.3% | 0.00% | – |
| Q1 2015 | $66,000 | -97.8% | 694 | -97.4% | 0.00% | -100.0% |
| Q4 2014 | $3,008,000 | +870.3% | 26,858 | +430.0% | 0.00% | – |
| Q3 2014 | $310,000 | -12.2% | 5,068 | -35.3% | 0.00% | – |
| Q2 2014 | $353,000 | +54.8% | 7,828 | +34.3% | 0.00% | – |
| Q1 2014 | $228,000 | +7500.0% | 5,830 | +3349.7% | 0.00% | – |
| Q4 2013 | $3,000 | -70.0% | 169 | -56.2% | 0.00% | – |
| Q3 2013 | $10,000 | – | 386 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |